Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma von Breitkreutz, I, Raab, M S, Vallet, S, Hideshima, T, Raje, N, Mitsiades, C, Chauhan, D, Okawa, Y, Munshi, N C, Richardson, P G, Anderson, K C

Volltext

Real-world analysis of teclistamab in 123 RRMM patients from Germany von Riedhammer, C., Bassermann, F., Besemer, B., Bewarder, M., Brunner, F., Carpinteiro, A., Einsele, H., Faltin, J., Frenking, J., Gezer, D., Goldman-Mazur, S., Hänel, M., Hoegner, M., Kortuem, K. M., Krönke, J., Kull, M., Leitner, T., Mann, C., Mecklenbrauck, R., Merz, M., Morgner, A., Nogai, A., Raab, M. S., Teipel, R., Wäsch, R., Rasche, L.

Volltext

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents von Merz, M., Neben, K., Raab, M.S., Sauer, S., Egerer, G., Hundemer, M., Hose, D., Kunz, C., Heiß, C., Ho, A.D., Goldschmidt, H., Hillengass, J.

Volltext

Targeting the Pim kinases in multiple myeloma von Keane, N A, Reidy, M, Natoni, A, Raab, M S, O'Dwyer, M

Volltext

Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma von Waizenegger, J. S., Ben-Batalla, I., Weinhold, N., Meissner, T., Wroblewski, M., Janning, M., Riecken, K., Binder, M., Atanackovic, D., Taipaleenmaeki, H., Schewe, D., Sawall, S., Gensch, V., Cubas-Cordova, M., Seckinger, A., Fiedler, W., Hesse, E., Kröger, N., Fehse, B., Hose, D., Klein, B., Raab, M. S., Pantel, K., Bokemeyer, C., Loges, S.

Volltext

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation von Xu, J, Pfarr, N, Endris, V, Mai, E K, Md Hanafiah, N H, Lehners, N, Penzel, R, Weichert, W, Ho, A D, Schirmacher, P, Goldschmidt, H, Andrulis, M, Raab, M S

Volltext

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma von Waizenegger, J S, Ben-Batalla, I, Weinhold, N, Meissner, T, Wroblewski, M, Janning, M, Riecken, K, Binder, M, Atanackovic, D, Taipaleenmaeki, H, Schewe, D, Sawall, S, Gensch, V, Cubas-Cordova, M, Seckinger, A, Fiedler, W, Hesse, E, Kröger, N, Fehse, B, Hose, D, Klein, B, Raab, M S, Pantel, K, Bokemeyer, C, Loges, S

Volltext

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology von Mai, Elias K., Hielscher, Thomas, Kloth, Jost K., Merz, Maximilian, Shah, Sofia, Hillengass, Michaela, Wagner, Barbara, Hose, Dirk, Raab, M.S., Jauch, Anna, Delorme, Stefan, Goldschmidt, Hartmut, Weber, Marc-André, Hillengass, Jens

Volltext

Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure von Breitkreutz, I, Heiss, C, Perne, A, Beimler, J, Jäger, D, Egerer, G, Ho, A D, Neben, K, Zeier, M, Goldschmidt, H, Raab, M S

Volltext

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG‐DA... von Leypoldt, L., Gavriatopoulou, M., Besemer, B., Salwender, H., Raab, M.‐S., Nogai, A., Khandanpour, C., Runde, V., Zago, M., Martus, P., Goldschmidt, H., Bokemeyer, C., Dimopoulos, M., Weisel, K.

Volltext

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE‐REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1‐3 PRIOR LINES OF THERAPY: CARTITUDE‐2 BIOLOGICAL CORRELATIVE ANALYSES... von Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M.‐S., Scheid, C., Schecter, J. M., De Braganca, K. C., Varsos, H., Yeh, T.‐M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M., Cohen, Y. C.

Volltext

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR... von Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez‐Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.‐S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.

Volltext

Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14) von HUNDEMER, M, KLEIN, U, GOLDSCHMIDT, H, HOSE, D, RAAB, M.-S, CREMER, F. W, JAUCH, A, BENNER, A, HEISS, C, MOOS, M, HO, A. D

Volltext

P08: CARTITUDE‐2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B‐CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY, IN LENALIDOMIDE‐REFRACTORY PATIENTS WITH PROGRESS... von Einsele, H, Cohen, AD, Delforge, M, Hillengass, J, Goldschmidt, H, Weisel, K, Raab, M‐S, Scheid, C, Schecter, JM, De Braganca, KC, Varsos, H, Yeh, T‐M, Wang, L, Vogel, M, Corsale, C, Akram, M, Pacaud, L, Nesheiwat, T, Agha, M, Cohen, YC

Volltext

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial von Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P

Volltext

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma von Mai, E K, Bertsch, U, Dürig, J, Kunz, C, Haenel, M, Blau, I W, Munder, M, Jauch, A, Schurich, B, Hielscher, T, Merz, M, Huegle-Doerr, B, Seckinger, A, Hose, D, Hillengass, J, Raab, M S, Neben, K, Lindemann, H-W, Zeis, M, Gerecke, C, Schmidt-Wolf, I G H, Weisel, K, Scheid, C, Salwender, H, Goldschmidt, H

Volltext

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield von BREITKREUTZ, I, LOKHORST, H. M, SALWENDER, H, HAENE, A, SONNEVELD, P, COLDSCHMIDT, H, RAAB, M. S, VAN DER HOLT, B, CREMER, F. W, HERRMANN, D, GLASMACHER, A, SCHMIDT-WOLF, I. G. H, BLAU, I. W, MARTIN, H

Volltext

Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma von Merz, M, Hielscher, T, Wagner, B, Sauer, S, Shah, S, Raab, M S, Jauch, A, Neben, K, Hose, D, Egerer, G, Weber, M-A, Delorme, S, Goldschmidt, H, Hillengass, J

Volltext

BRAF-Inhibitoren in der Therapie des multiplen Myeloms von Kunze, A, Giesen, N, Raab, M.-S

Volltext

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma von Weinhold, Niels, Kirn, Desiree, Seckinger, Anja, Hielscher, Thomas, Granzow, Martin, Bertsch, Uta, Egerer, Gerlinde, Salwender, Hans, Blau, Igor W, Weisel, Katja, Hillengass, Jens, Raab, Marc S, Hose, Dirk, Goldschmidt, Hartmut, Jauch, Anna

Volltext